GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (OTCPK:BPTSY) » Definitions » Total Current Assets

Biophytis (Biophytis) Total Current Assets : $9.65 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biophytis Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Biophytis's total current assets for the quarter that ended in Dec. 2023 was $9.65 Mil.


Biophytis Total Current Assets Historical Data

The historical data trend for Biophytis's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biophytis Total Current Assets Chart

Biophytis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.34 29.21 35.44 19.68 9.65

Biophytis Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.44 32.07 19.68 12.33 9.65

Biophytis Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Biophytis's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Biophytis's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Biophytis  (OTCPK:BPTSY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Biophytis's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6.472-17.284+0.75 * 0.324+0.5 * 0
=-10.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biophytis Total Current Assets Related Terms

Thank you for viewing the detailed overview of Biophytis's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biophytis (Biophytis) Business Description

Traded in Other Exchanges
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

Biophytis (Biophytis) Headlines

From GuruFocus